Olubunmi Adebiyi
University of KwaZulu-Natal, South Africa
Posters-Accepted Abstracts: J Diabetes Metab
Cardiac hypertrophy in Type 1 Diabetes Mellitus is attributed to increased oxidative stress associated activation of c-Jun Nuclear Kinase (JNK). We investigated the effects of naringin on hyperglycemia-associated oxidative stress, activation of JNK-1 and cardiac hypertrophy. Male Sprague-Dawley rats (225-250 g) (n=7) were divided into 6 groups. Groups I and II were orally treated with distilled water {3.0 ml/kg bodyweight/day (BW)} and naringin (50 mg/kg BW), respectively. Groups III-VI were rendered diabetic by a single i.p injection of 60 mg/kg BW of streptozotocin (STZ). Groups III, IV, V and VI were further treated with subcutaneous insulin (4.0 I.U, twice daily), naringin (50 mg/kg BW), distilled water (3.0 ml/kg) and ramipril (3.0 mg/kg BW), respectively. After 56 days, the animals were sacrificed then plasma and cardiac tissues obtained for further analysis. Naringin treatment of diabetic rats significantly reversed oxidative stress, lipid peroxidation, proteins oxidation, cardiac hypertrophy indices, and JNK protein activation compared to untreated diabetic animals. Our results do suggest that naringin mitigates cardiac hypertrophy by inhibiting oxidative stress leading to inactivation of JNK-1. Naringin supplements could therefore ameliorate cardiac hypertrophy in diabetic patients.
Email: olubunmide@gmail.com
